ImmunOs Therapeutics Appoints Claudia Berger as SVP Clinical Development
- Strengthened clinical development expertise to ensure smooth transition into the clinic
Schlieren (Zurich Area), Switzerland. – September 30, 2021 – ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that Claudia Berger has been appointed as Senior Vice President Clinical Development, further strengthening the Company’s clinical development and operations expertise as it prepares for initial clinical trials.
Claudia Berger is a proven expert in the field of clinical development and has been focusing on clinical trial operations and project management for more than 15 years. Before joining ImmunOs Therapeutics, she served as Director Clinical Operations at Inflazome Ltd, an Irish company recently acquired by Roche. Prior to that, she headed clinical operations at several biopharmaceutical companies such as Kinarus AG and Delenex Therapeutics, leading Phase I/II clinical programs, including profiling, biomarker and proof-of-concept studies with both biologics and small molecules and establishing quality assurance systems. From 2007 to 2012, she held several positions of increasing responsibility at the Novartis Institute for Biomedical Research (NIBR), most recently as Principal Clinical Scientist. Claudia Berger holds a Master of Science Degree in Pharmacy and a Diploma as a University Professional of Advanced Studies in Pharmaceutical Medicine.
“It is a great pleasure to welcome Claudia Berger as SVP Clinical Development,” said Prof. Dr. med. Christoph Renner, Chief Medical Officer at ImmunOs Therapeutics. “As we are preparing the first clinical trials of our lead compound iosH2 in solid and liquid tumors, her strong clinical expertise will be very valuable for setting up a state-of-the-art clinical development infrastructure and for ensuring a smooth transition into the clinic.”
“I am looking forward to working with the team at ImmunOs,” said Claudia Berger, SVP Clinical Development at ImmunOs Therapeutics. “Advancing a sophisticated pipeline of novel HLA-based immuno-modulatory therapeutics through clinical development will be a demanding, but hopefully rewarding task and I am delighted to join this dynamic team that is committed to bringing such innovative immunotherapeutics to patients.”
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG focuses on the development of a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases. The Company has established a proprietary R&D platform for the development of HLA-based therapeutics addressing multiple targets via a single fusion protein. Its novel compounds are fully human and modulate the innate immune system. ImmunOs Therapeutics´ lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.
ImmunOs Therapeutics AG is supported by top-tier investors including Pfizer Ventures, BioMed Partners, Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd and UZH Life Sciences Fund as well as undisclosed private investors.
The Company is a spin-off from the Universities of Zurich and Basel and based in Schlieren, Switzerland.
For more information, please visit www.immunostherapeutics.com
ImmunOs Therapeutics AG
8952 Schlieren (Zurich Area), Switzerland
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68